KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to $9.5 million.

  • Castle Biosciences' Change in Accured Expenses rose 4742.73% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 2882.1%. This contributed to the annual value of $3.6 million for FY2024, which is 2129.93% down from last year.
  • As of Q3 2025, Castle Biosciences' Change in Accured Expenses stood at $9.5 million, which was up 4742.73% from $7.1 million recorded in Q2 2025.
  • Castle Biosciences' Change in Accured Expenses' 5-year high stood at $9.5 million during Q3 2025, with a 5-year trough of -$14.7 million in Q1 2025.
  • In the last 5 years, Castle Biosciences' Change in Accured Expenses had a median value of $4.5 million in 2023 and averaged $1.3 million.
  • Data for Castle Biosciences' Change in Accured Expenses shows a peak YoY increase of 13779.62% (in 2022) and a maximum YoY decrease of 7740.45% (in 2022) over the last 5 years.
  • Quarter analysis of 5 years shows Castle Biosciences' Change in Accured Expenses stood at $3.2 million in 2021, then skyrocketed by 51.0% to $4.8 million in 2022, then surged by 35.52% to $6.5 million in 2023, then decreased by 25.34% to $4.9 million in 2024, then surged by 94.22% to $9.5 million in 2025.
  • Its Change in Accured Expenses was $9.5 million in Q3 2025, compared to $7.1 million in Q2 2025 and -$14.7 million in Q1 2025.